According to a recent study on triple-negative BRCA [22], the research team used a corresponding single anti CD8+ T cells in immune treatment to activate related anti-tumor immune mechanism, while ICIs activated follicular helper T cells that stimulated B cells to produce antibodies. The gene discussed is CD8A; the disease is neoplasm.